J.PereiraM
Clinical trials show that approximately 70% of weight loss returns within one year after stopping treatment, though individual outcomes vary significantly based on genetic factors and sustained behavioral changes
doi: 10.1023/B:MCBI.0000028747.92084.42
"For someone with type 2 diabetes or significant obesity, the cardiovascular, kidney and metabolic benefits [of these medications] are large and well-established, and stopping abruptly carries its own risks, so any change should be a conversation with your prescriber," he said
Additionally, Wegovy commonly causes gastrointestinal side effects such as nausea, vomiting, diarrhoea, and constipation, which affect a substantial proportion of users according to the SmPC
Tirzepatide is relatively new, and research is ongoing